The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge
Open accessAbstract
Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the standard of care for TNBC treatment, but unfortunately, patients frequently develop resistance. Accordingly, in recent years, tremendous effort has been made into elucidating the mechanisms of TNBC chemoresistance with the goal of identifying new molecular targets. It has become evident that the development of TNBC chemoresistance is multifaceted and based on the elaborate interplay of the tumor microenvironment, drug efflux, cancer stem cells, and bulk tumor cells. Alterations of multiple signaling pathways govern these interactions. Moreover, TNBC’s high heterogeneity, highlighted in the existence of several molecular signatures, presents a significant obstacle to successful treatment. In the present, in-depth review, we explore the contribution of key mechanisms to TNBC chemoresistance as well as emerging strategies to overcome them. We discuss novel anti-tumor agents that target the components of these mechanisms and pay special attention to their current clinical development while emphasizing the challenges still ahead of successful TNBC management. The evidence presented in this review outlines the role of crucial pathways in TNBC survival following chemotherapy treatment and highlights the importance of using combinatorial drug strategies and incorporating biomarkers in clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 1×
“Several studies have reported ABCG2 as an important marker of the so-called, side population of CSC [48].”
BackgroundMetastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Hedgehog Signaling and Bmi-1 Regulate Self-renewal of Normal and Malignant Human Mammary Stem Cells
Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0054 · Cited by 1,244
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Latent TGF-β structure and activation
Shi, M., Zhu, J., Wang, R., Chen, X., Mi, L., Walz, T., & Springer, T. A. (2011) · Nature · doi:10.1038/nature10152 · Cited by 1,013
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M. B., Hatziapostolou, M., Lim, E., Tam, W. L., Ni, M., Chen, Y., et al. (2014) · Nature · doi:10.1038/nature13119 · Cited by 817
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
The role of the Hedgehog signaling pathway in cancer: A comprehensive review
Skoda, A. M., Simovic, D., Karin, V., Kardum, V., Vranic, S., & Serman, L. (2018) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2018.2756 · Cited by 781
The Varied Roles of Notch in Cancer
Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100127 · Cited by 710
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
The Wnt signaling pathway in cancer
Duchartre, Y., Kim, Y.-M., & Kahn, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 548
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Harrison, H., Farnie, G., Howell, S. J., Rock, R. E., Stylianou, S., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1681 · Cited by 543
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
Hartman, Z. C., Poage, G. M., den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Mills, G. B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4524-t · Cited by 409
Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1532 · Cited by 400
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis
Vaupel, P. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s3-21 · Cited by 383
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
Chouaib, S., Noman, M. Z., Kosmatopoulos, K., & Curran, M. A. (2017) · Oncogene · doi:10.1038/onc.2016.225 · Cited by 365
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics
Gerweck, L. E., Vijayappa, S., & Kozin, S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0024 · Cited by 362
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 2×
“Thirdly, cytotoxic effects of a number of drugs are oxygen dependent [102].”
BackgroundLehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 337
Advances in the Systemic Treatment of Triple-Negative Breast Cancer
Lebert, J. M., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018) · Current Oncology · doi:10.3747/co.25.3954 · Cited by 330
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies
Khan, A., Ahmed, E., Elareer, N., Junejo, K., Steinhoff, M., & Uddin, S. (2019) · Cells · doi:10.3390/cells8080840 · Cited by 297
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279
A Time to Kill: Targeting Apoptosis in Cancer
Koff, J., Ramachandiran, S., & Bernal-Mizrachi, L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16022942 · Cited by 279
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
Schott, A. F., Landis, M. D., Dontu, G., Griffith, K. A., Layman, R. M., Krop, I., Paskett, L. A., Wong, H., Dobrolecki, L. E., Lewis, M. T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3326 · Cited by 277
Asiedu, M. K., Ingle, J. N., Behrens, M. D., Radisky, D. C., & Knutson, K. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4554 · Cited by 270
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Asghar, U. S., Barr, A. R., Cutts, R., Beaney, M., Babina, I., Sampath, D., Giltnane, J., Lacap, J. A., Crocker, L., Young, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0369 · Cited by 268
Devulapally, R., Sekar, N. M., Sekar, T. V., Foygel, K., Massoud, T. F., Willmann, J. K., & Paulmurugan, R. (2015) · ACS Nano · doi:10.1021/nn507465d · Cited by 260
Wnt signaling in triple negative breast cancer is associated with metastasis
Dey, N., Barwick, B. G., Moreno, C. S., Ordanic-Kodani, M., Chen, Z., Oprea-Ilies, G., Tang, W., Catzavelos, C., Kerstann, K. F., Sledge, G. W., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-537 · Cited by 255
HIF-1 in cancer therapy: two decade long story of a transcription factor
Soni, S., & Padwad, Y. S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1301680 · Cited by 251 · cited 1×
“Since the discovery of HIFs, many inhibitors with diverse modes of action have been identified, but none have progressed to clinical use [119].”
BackgroundSHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors
Montagner, M., Enzo, E., Forcato, M., Zanconato, F., Parenti, A., Rampazzo, E., Basso, G., Leo, G., Rosato, A., Bicciato, S., et al. (2012) · Nature · doi:10.1038/nature11207 · Cited by 247
Liu, Y.-R., Jiang, Y.-Z., Xu, X.-E., Yu, K.-D., Jin, X., Hu, X., Zuo, W.-J., Hao, S., Wu, J., Liu, G.-Y., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0690-8 · Cited by 226
Siddharth, S., & Sharma, D. (2018) · Cancers · doi:10.3390/cancers10120514 · Cited by 224
Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer
Shibata, M., & Hoque, M. O. (2019) · Cancers · doi:10.3390/cancers11050732 · Cited by 223
Ng, L., Kaur, P., Bunnag, N., Suresh, J., Sung, I., Tan, Q., Gruber, J., & Tolwinski, N. (2019) · Cells · doi:10.3390/cells8080826 · Cited by 212
Loibl, S., Müller, B. M., von Minckwitz, G., Schwabe, M., Roller, M., Darb-Esfahani, S., Ataseven, B., du Bois, A., Fissler-Eckhoff, A., Gerber, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1715-8 · Cited by 211
Lee, H. E., Kim, J. H., Kim, Y. J., Choi, S. Y., Kim, S.-W., Kang, E., Chung, I. Y., Kim, I. A., Kim, E. J., Choi, Y., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.159 · Cited by 200
MCL-1 is a prognostic indicator and drug target in breast cancer
Campbell, K. J., Dhayade, S., Ferrari, N., Sims, A. H., Johnson, E., Mason, S. M., Dickson, A., Ryan, K. M., Kalna, G., Edwards, J., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0035-2 · Cited by 200
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Tan, E. Y., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., Candiloro, I., Pezzella, F., Gatter, K. C., Millar, E. K. A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604844 · Cited by 195
Molecular Pathways: Targeting the TGF-β Pathway for Cancer Therapy
Smith, A. L., Robin, T. P., & Ford, H. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3224 · Cited by 193
Hypoxia and Selective Autophagy in Cancer Development and Therapy
Daskalaki, I., Gkikas, I., & Tavernarakis, N. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00104 · Cited by 188 · cited 1×
“These include: increased expression of ABC transporters (including ABCG2 and ABCC1) [105,106]; decreased proliferation [102]; complex modulation of cellular senescence and apoptosis [102]; induction of autophagy that aids in tumor survival [107]; enhanced genetic instability and subsequent clonal selection of aggressi…”
BackgroundMicroRNAs in regulation of triple-negative breast cancer progression
Piasecka, D., Braun, M., Kordek, R., Sadej, R., & Romanska, H. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2689-2 · Cited by 185
Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
Farabaugh, S. M., Boone, D. N., & Lee, A. V. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00059 · Cited by 182
β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
Xu, J., Prosperi, J. R., Choudhury, N., Olopade, O. I., & Goss, K. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117097 · Cited by 180
Insulin-like Growth Factor Receptor Inhibitors: Baby or the Bathwater?
Yee, D. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs258 · Cited by 177
Xu, X., Zhang, L., He, X., Zhang, P., Sun, C., Xu, X., Lu, Y., & Li, F. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.139 · Cited by 175
STAT3: a multifaceted oncoprotein
Guanizo, A. C., Fernando, C. D., Garama, D. J., & Gough, D. J. (2018) · Growth Factors · doi:10.1080/08977194.2018.1473393 · Cited by 174
PAN, H., ZHOU, W., HE, W., LIU, X., DING, Q., LING, L., ZHA, X., & WANG, S. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.990 · Cited by 171
Steelman, L. S., Navolanic, P. M., Sokolosky, M. L., Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Stadelman, K. M., Terrian, D. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.49 · Cited by 170
D’Ignazio, L., & Rocha, S. (2016) · Cells · doi:10.3390/cells5010010 · Cited by 168
Li, H.-Y., Liang, J.-L., Kuo, Y.-L., Lee, H.-H., Calkins, M. J., Chang, H.-T., Lin, F.-C., Chen, Y.-C., Hsu, T.-I., Hsiao, M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0918-2 · Cited by 168
The paradoxical functions of EGFR during breast cancer progression
Ali, R., & Wendt, M. K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.42 · Cited by 167
Jang, G.-B., Hong, I.-S., Kim, R.-J., Lee, S.-Y., Park, S.-J., Lee, E.-S., Park, J. H., Yun, C.-H., Chung, J.-U., Lee, K.-J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2041 · Cited by 163
O'Toole, S. A., Machalek, D. A., Shearer, R. F., Millar, E. K. A., Nair, R., Schofield, P., McLeod, D., Cooper, C. L., McNeil, C. M., McFarland, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3738 · Cited by 163
Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast
Rustighi, A., Zannini, A., Tiberi, L., Sommaggio, R., Piazza, S., Sorrentino, G., Nuzzo, S., Tuscano, A., Eterno, V., Benvenuti, F., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302909 · Cited by 158
Teng, Y. H.-F., Tan, W.-J., Thike, A., Cheok, P. Y., Tse, G. M.-K., Wong, N.-S., Yip, G. W. C., Bay, B., & Tan, P. (2011) · Breast Cancer Research · doi:10.1186/bcr2857 · Cited by 154
FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer
Han, B., Qu, Y., Jin, Y., Yu, Y., Deng, N., Wawrowsky, K., Zhang, X., Li, N., Bose, S., Wang, Q., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.063 · Cited by 150
Ma, F., Li, H., Wang, H., Shi, X., Fan, Y., Ding, X., Chen, L., Zhan, Q., Qian, H., & Xu, B. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.022 · Cited by 150
Wu, S., & Fu, L. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0775-3 · Cited by 146
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, N., & Konopleva, M. Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0895 · Cited by 143
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
Bhateja, P., Cherian, M. A., Majumder, S., & Ramaswamy, B. (2019) · Cancers · doi:10.3390/cancers11081126 · Cited by 143
Balko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltnane, J. M., Dávila‐González, D., Wang, K., Sanchez, V. M., Dean, P. T., Combs, S. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3001 · Cited by 142
Regulation of Programmed Cell Death by NF-κB and its Role in Tumorigenesis and Therapy
Fan, Y., Dutta, J., Gupta, N., Fan, G., & Gélinas, C. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_11 · Cited by 140
zu Schwabedissen, H. E. M., Grube, M., Dreisbach, A., Jedlitschky, G., Meissner, K., Linnemann, K., Fusch, C., Ritter, C. A., Völker, U., & Kroemer, H. K. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007591 · Cited by 140
Qiu, M., Peng, Q., Jiang, I., Carroll, C., Han, G., Rymer, I., Lippincott, J., Zachwieja, J., Gajiwala, K. S., Kraynov, E. A., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.023 · Cited by 139
Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
Sissung, T. M., Baum, C. E., Kirkland, C. T., Gao, R., Gardner, E. R., & Figg, W. D. (2009) · Molecular Biotechnology · doi:10.1007/s12033-009-9220-6 · Cited by 134
MRP8/ABCC11 directly confers resistance to 5-fluorouracil
Oguri, T., Bessho, Y., Achiwa, H., Ozasa, H., Maeno, K., 前田, 浩., Sato, S., & Ueda, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0529 · Cited by 132
Litzenburger, B. C., Creighton, C. J., Tsimelzon, A. I., Chan, B. T.-Y., Hilsenbeck, S. G., Wang, T., Carboni, J. M., Gottardis, M. M., Huang, F., Chang, J. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1903 · Cited by 132
Breast cancer, side population cells and ABCG2 expression
Britton, K. M., Eyre, R., Harvey, I. J., Stemke‐Hale, K., Browell, D., Lennard, T. W. J., & Meeson, A. P. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.041 · Cited by 126
Guerrab, A. E., Bamdad, M., Kwiatkowski, F., Bignon, Y., Penault-Llorca, F. M., & Aubel, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12037 · Cited by 122
The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells
Kim, H., Lin, Q., Glazer, P. M., & Yun, Z. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0944-8 · Cited by 122
Harris, L. G., Pannell, L. K., Singh, S., Samant, R. S., & Shevde, L. A. (2011) · Oncogene · doi:10.1038/onc.2011.496 · Cited by 121
Nabholtz, J., Abrial, C., Mouret‐Reynier, M., Dauplat, M.-M., Weber, B. E., Gligorov, J., Forest, A. M., Trédan, O., Vanlemmens, L., Petit, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu183 · Cited by 121
Echavarría, I., López‐Tarruella, S., Picornell, A. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1912 · Cited by 120
Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer
Lv, Y., Zhao, S., Han, J., Zheng, L., Yang, Z., & Zhao, L. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s82835 · Cited by 119
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
Ferraro, D. A., Gaborit, N., Maron, R., Cohen‐Dvashi, H., Porat, Z., Pareja, F. G., Lavi, S., Lindzen, M., Ben‐Chetrit, N., Sela, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220763110 · Cited by 118
Why is PTEN an important tumor suppressor?
Li, L., & Ross, A. H. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21593 · Cited by 116
Revisiting the IGF-1R as a breast cancer target
Ekyalongo, R. C., & Yee, D. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0017-y · Cited by 114
Wei, W., Tweardy, D. J., Zhang, M., Zhang, X., Landua, J. D., Petrovic, I., Bu, W., Roarty, K. P., Hilsenbeck, S. G., Rosen, J. M., et al. (2014) · Stem Cells · doi:10.1002/stem.1752 · Cited by 112
Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers
Choy, L., Hagenbeek, T. J., Solon, M., French, D. M., Finkle, D., Shelton, A., Venook, R., Brauer, M. J., & Siebel, C. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1022 · Cited by 106
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
Mauro, C. D., Rosa, R., D'Amato, V., Ciciola, P., Servetto, A., Marciano, R., Orsini, R. C., Formisano, L., Falco, S. D., Cicatiello, V., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.116 · Cited by 103
Exploring Molecular Pathways of Triple-Negative Breast Cancer
Ossovskaya, V., Wang, Y., Budoff, A., Xu, Q., Lituev, A., Potapova, O., Vansant, G., Monforte, J., & Daraselia, N. (2011) · Genes & Cancer · doi:10.1177/1947601911432496 · Cited by 101
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96
Ban, H. S., Kim, B., Lee, H., Kim, H. M., Harmalkar, D. S., Nam, M., Park, S., Lee, K., Park, J.-T., Kim, I., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.235 · Cited by 96
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells
He, L., Gu, J. H., Lim, L. Y., Yuan, Z., & Mo, J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00313 · Cited by 94
Locatelli, M., Aftimos, P. G., Dees, E. C., LoRusso, P. M., Pegram, M. D., Awada, A. H., Huang, B., Cesari, R., Jiang, Y., Shaik, M. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13727 · Cited by 93
Kuo, W.-Y., Hwu, L., Wu, C.-Y., Lee, J.-S., Chang, C., & Liu, R.-S. (2017) · Theranostics · doi:10.7150/thno.16827 · Cited by 92
Function of insulin‑like growth factor 1 receptor in cancer resistance to chemotherapy (Review)
Yuan, J., Yin, Z., Tao, K., Wang, G., & Gao, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7276 · Cited by 92
The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis
Fusella, F., Seclì, L., Busso, E., Křepelová, A., Moiso, E., Rocca, S., Conti, L., Annaratone, L., Rubinetto, C., Grand, M. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01829-1 · Cited by 92
Tormo, E., Ballester, S., Adam‐Artigues, A., Burgués, O., Alonso, E., Bermejo, B., Menéndez, S., Zazo, S., Madoz‐Gúrpide, J., Rovira, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41472-y · Cited by 89
Targeting multidrug resistance in cancer by natural chemosensitizers
Hamed, A. R., Abdel‐Azim, N. S., Shams, K. A., & Hammouda, F. M. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0043-8 · Cited by 88
Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
He, J., Lee, H., Saha, S., Ruan, D., Guo, H., & Chan, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1512-6 · Cited by 88
MicroRNAs in the prognosis of triple-negative breast cancer
Lü, L., Mao, X., Shi, P., He, B., Xu, K., Zhang, S., & Wang, J. (2017) · Medicine · doi:10.1097/md.0000000000007085 · Cited by 86
British Society of Breast Radiology Annual Scientific Meeting 2016
Azmil, A., Bansal, G. J., Davies, E. L., Wallis, M., Kilburn‐Toppin, F., Taylor-Phillip, S., Buckley, A., Healy, N. A., Quinn, A., O’Keeffe, S., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0766-5 · Cited by 86
Zhang, X., Liu, X., Luo, J., Xiao, W. L., Ye, X., Chen, M., Li, Y., & Zhang, G.-J. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.67 · Cited by 85
The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
Zhu, X., & Zhou, W. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00159 · Cited by 84
Corda, G., Sala, G., Lattanzio, R., Iezzi, M., Sallese, M., Fragassi, G., Lamolinara, A., Mirza, H., Barcaroli, D., Ermler, S., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4841 · Cited by 82
Cheng, C., Shi, L., Wang, X., Wang, S.-X., Wan, X.-Q., Liu, S., Wang, Y., Lü, Z., Wang, L., & Ding, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4399 · Cited by 82
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
Smith, D. C., Chugh, R. K., Patnaik, A., Papadopoulos, K. P., Wang, M., Kapoun, A. M., Xu, L., Dupont, J., Stagg, R., & Tolcher, A. W. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0714-6 · Cited by 82
Simões‐Wüst, A. P., Schürpf, T., Hall, J., Stahel, R. A., & Zangemeister‐Wittke, U. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020543004400 · Cited by 80
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Inao, T., Iida, Y., Moritani, T., Okimoto, T., Tanino, R., Kotani, H., & Harada, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25370 · Cited by 79
Matsuda, N., Wang, X., Lim, B., Krishnamurthy, S., Álvarez, R. H., Willey, J. S., Parker, C. A., Song, J., Shen, Y., Hu, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1436 · Cited by 76
Koike, Y., Ohta, Y., Saitoh, W., Yamashita, T., Kanomata, N., Moriya, T., & Kurebayashi, J. (2017) · Breast Cancer · doi:10.1007/s12282-017-0757-0 · Cited by 75
Ji (2010) · Oncology Reports · doi:10.3892/or_00000712 · Cited by 74
miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer
Liu, S., Wang, Z., Liu, Z., Shi, S., Zhang, Z., Zhang, J., & Lin, H. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy041 · Cited by 74
Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8392 · Cited by 72
Ueng, S., Chen, S., Chang, Y., Hsueh, S., Lin, Y., Chien, H., Lo, Y.-F., Shen, S., & Hsueh, C. (2012) · Europe PMC (PubMed Central) · Cited by 70
Kwon, Y.-J., Hurst, D. R., Steg, A. D., Yuan, K., Vaidya, K. S., Welch, D. R., & Frost, A. R. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9382-z · Cited by 69
Greer, Y. E., Gilbert, S. F., Gril, B., Narwal, R., Brooks, D. L. P., Tice, D. A., Steeg, P. S., & Lipkowitz, S. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1116-1 · Cited by 68
Role of Wnt Co-Receptor LRP6 in Triple Negative Breast Cancer Cell Migration and Invasion
Ma, J., Lü, W., Chen, D., Xu, B., & Li, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25956 · Cited by 67
Ahmed, K., Koval, A., Xu, J., Bodmer, A., & Katanaev, V. L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.018 · Cited by 67
Arumugam, A., Subramani, R., Nandy, S., Terreros, D. A., Dwivedi, A. K., Saltzstein, E. C., & Lakshmanaswamy, R. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0197-8 · Cited by 66
A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Choi, H. J., Heo, J. H., Park, J. Y., Jeong, J. Y., Cho, H. J., Park, K. S., Kim, S. H., Moon, Y. W., Kim, J. S., & An, H. J. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.012 · Cited by 66
Kim, B., Stephen, S. L., Hanby, A. M., Horgan, K. J., Perry, S., Richardson, J. L., Roundhill, E. A., Valleley, E. M. A., Verghese, E. T., Williams, B. J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1625-y · Cited by 64
İnanç, M., Özkan, M., Karaca, H., Berk, V., Bozkurt, O., Duran, A. O., Özaslan, E., Akgün, H., Tekelioğlu, F., & Elmalı, F. (2013) · Medical Oncology · doi:10.1007/s12032-013-0801-7 · Cited by 64
Wang, Y., Zhao, L., Xiao, Q., Jiang, L., He, M., Bai, X., Ma, M., Jiao, X., & Wei, M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.034 · Cited by 64
O'Connor, R. A., O’Leary, M., Ballot, J., Collins, C. D., Kinsella, P., Mager, D. E., Arnold, R. D., O’Driscoll, L., Larkin, A., Kennedy, S., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0240-7 · Cited by 62
Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity
Begalli, F., Bennett, J., Capece, D., Verzella, D., D’Andrea, D., Tornatore, L., & Franzoso, G. (2017) · Biomedicines · doi:10.3390/biomedicines5030050 · Cited by 62
Sims‐Mourtada, J., Opdenaker, L. M., Davis, J. J., Arnold, K. M., & Flynn, D. C. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22225 · Cited by 61
miRNAs as Potential Treatment Targets and Treatment Options in Cancer
Petrović, N., & Ergün, S. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0314-8 · Cited by 61
Zhang, G.-N., Zhang, Y., Wang, Y., Gupta, P., Ashby, C. R., Alqahtani, S., Deng, T., Bates, S. E., Kaddoumi, A., Wurpel, J. N. D., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.040 · Cited by 61
Interleukin‐6 contributes to chemoresistance in MDA‐MB‐231 cells via targeting HIF‐1α
Wang, K., Zhu, X., Zhang, K., Yin, Y., Chen, Y., & Zhang, T. (2018) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22039 · Cited by 61
Schmid, P., Abraham, J., Chan, S. Y. T., Wheatley, D. A., Brunt, M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1007 · Cited by 61
Yang, C., He, Y., Zhang, H., Liu, Y., Wang, W., Du, Y., & Gao, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3681 · Cited by 59
Liu, M., Gong, C., Xu, R., Chen, Y., & Wang, X. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0168-7 · Cited by 59
Moreira, M. P., Braga, L. D. C., Cassali, G. D., & Silva, L. M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.018 · Cited by 56
Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics
Wang, S., Bai, L., Lü, J., Liu, L., Yang, C., & Sun, H. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9265-1 · Cited by 52
Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer
Lei, J., Fan, L., Wei, G., Chen, X., Duan, W., Xu, Q., Wei, S., Wang, K., & Li, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2948-z · Cited by 52
Peng, H., Dong, Z., Qi, J. W., Yang, Y., Liu, Y., Li, Z., Xu, J., & Zhang, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005676 · Cited by 52
Gangrade, A., Pathak, V., Augelli‐Szafran, C. E., Wei, H., Oliver, P. G., Suto, M. J., & Buchsbaum, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051524 · Cited by 51
Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
Li, Z.-L., Chen, C., Yang, Y., Wang, C., Yang, T., Yang, X. P., & Liu, S. (2015) · PubMed · Cited by 50
Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer
Jin, M., Lee, H., Park, I. A., Chung, Y. R., Im, S., Lee, K.-H., Moon, H., Han, W., Kim, K., Kim, T., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1953-6 · Cited by 49
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
Kim, A., Jang, M. H., Lee, S. J., & Bae, Y. K. (2017) · Journal of Breast Cancer · doi:10.4048/jbc.2017.20.2.150 · Cited by 48
Diluvio, G., Gaudio, F. D., Giuli, M. V., Franciosa, G., Giuliani, E., Palermo, R., Besharat, Z. M., Pignataro, M. G., Vacca, A., d’Amati, G., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0051-9 · Cited by 47
Guestini, F., Ono, K., Miyashita, M., Ishida, T., Ohuchi, N., Nakagawa, S., Hirakawa, H., Tamaki, K., Ohi, Y., Rai, Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4985-6 · Cited by 47
Xiang, L., Liu, Z., Huan, Q., Su, P., Du, G.-J., Wang, Y., Gao, P., & Zhou, G. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-32 · Cited by 46
Ozretić, P., Alvir, I., Šarčević, B., Vujašković, Ž., Rendić-Miočević, Z., Roguljic, A., & Beketić-Orešković, L. (2017) · The International Journal of Biological Markers · doi:10.5301/ijbm.5000291 · Cited by 43
Shen, H., Yan, W., Yuan, J., Wang, Z., & Wang, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1231-y · Cited by 41
Heskamp, S., Boerman, O. C., Molkenboer‐Kuenen, J. D. M., Wauters, C. A. P., Strobbe, L. J. A., Mandigers, C. M. P. W., Bult, P., Oyen, W. J. G., van der Graaf, W. T. A., & van Laarhoven, H. W. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117745 · Cited by 40
Ling, X., Liu, X., Zhong, K. L., et al. (2015) · PubMed · Cited by 40
Xie, W., Zhang, Y., He, Y. Z., Zhang, K., Wan, G., Huang, Y., Zhou, Z., Huang, G., & Wang, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.08.004 · Cited by 38
Zhang, L., Zhang, X., Wang, X., He, M., & Qiao, S.-X. (2019) · Disease Markers · doi:10.1155/2019/7378967 · Cited by 37
Arnold, K., Pohlig, R. T., & Sims‐Mourtada, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6874 · Cited by 34
Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer
Li, W., Yang, H., Li, X., Han, L., Xu, N., & Shi, A. (2018) · Oncology Reports · doi:10.3892/or.2018.6805 · Cited by 34
Cowherd, S., Miller, L. D., Melin, S. A., Akman, S. A., Isom, S. P., Cole, J., Pullikuth, A., & Lawrence, J. A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026481 · Cited by 32
O'Connor, R. A., Heenan, M., Connolly, L., Larkin, A., & CLYNES, M. M. (2004) · PubMed · Cited by 32
Messeha, S. S., Zarmouh, N. O., Mendonca, P., Alwagdani, H., Kolta, M. G., & Soliman, K. F. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201116 · Cited by 29
The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
Porcelli, L., Giovannetti, E., Assaraf, Y. G., Jansen, G., Scheffer, G. L., Kathmann, I., Azzariti, A., Paradiso, A., & Peters, G. J. (2014) · Current Drug Targets · doi:10.2174/1389450116666141205145620 · Cited by 27
Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft
Bharti, S. K., Mironchik, Y., Wildes, F. B., Penet, M., Goggins, E. S., Krishnamachary, B., & Bhujwalla, Z. M. (2018) · Oncotarget · doi:10.18632/oncotarget.24569 · Cited by 27
Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
Xie, N., Mou, L., Yuan, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103463 · Cited by 21
Wu, C., Zhao, A., Tan, T., Wang, Y., & Shen, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7601 · Cited by 21
Abyaneh, H. S., Soleimani, A., Vakili, M. R., Soudy, R., Kaur, K., Cuda, F., Tavassoli, A., & Lavasanifar, A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040196 · Cited by 19
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 283
Breast Cancer Type Classification Using Machine Learning
Wu, J., & Hicks, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020061 · Cited by 260
Metadata
- Authors
- Nedeljković, M., & Damjanović, A.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-08-22
- Volume
- 8
- Issue
- 9
- Pages
- 957
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2969263349
- Cited by
- 870
- References
- 187
- FWCI
- 21.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.